


PHARMACEUTICAL 2019


Verastem Inc. Rank 208 of 363







PHARMACEUTICAL 2019





The relative strengths and weaknesses of Verastem Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Verastem Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 44% points. The greatest weakness of Verastem Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 110% points.

The company's Economic Capital Ratio, given in the ranking table, is 66%, being 29% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	253,259
Cost of Goods Sold	165
Intangible Assets	21,577
Liabilities, Current	37,077
Liabilities, Non-Current	1,123
Other Assets	1,031
Other Compr. Net Income	129
Other Expenses	6,233
Other Liabilities	114,737
Other Net Income	2,603
Other Revenues	52,274
Property and Equipment	1,369
Research and Development	43,648
Selling, General and Administrative Expense	77,265

Output Variable	Value in 1000 USD
Assets	277,236
Liabilities	152,937
Expenses	127,311
Revenues	52,274
Stockholders Equity	124,299
Net Income	-72,434
Comprehensive Net Income	-72,370
Economic Capital Ratio	66%

